Prime Medicine, Inc.
PRME
$3.27
-$0.03-0.91%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 2.15% | -31.59% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.15% | -31.59% | |||
| Cost of Revenue | -1.74% | -21.10% | |||
| Gross Profit | 1.84% | 20.80% | |||
| SG&A Expenses | 18.10% | 31.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.17% | -10.42% | |||
| Operating Income | -4.21% | 9.94% | |||
| Income Before Tax | -6.60% | 8.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.60% | 8.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.60% | 8.90% | |||
| EBIT | -4.21% | 9.94% | |||
| EBITDA | -4.42% | 10.29% | |||
| EPS Basic | -6.73% | 17.52% | |||
| Normalized Basic EPS | -4.54% | 18.58% | |||
| EPS Diluted | -6.73% | 17.52% | |||
| Normalized Diluted EPS | -4.54% | 18.58% | |||
| Average Basic Shares Outstanding | -0.11% | 10.47% | |||
| Average Diluted Shares Outstanding | -0.11% | 10.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||